Phase 3 open-label trial in 256 patients with advanced melanoma, mostly acral subtype: first-line toripalimab improved progression-free survival vs dacarbazine (HR 0.71, 95% CI 0.53-0.95); grade 3 or worse treatment-related adverse events occurred in 28.3%.
RCTn = 256
Sheng et al. Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial